These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
203 related articles for article (PubMed ID: 12431074)
1. The practical synthesis of a novel and highly potent analogue of bryostatin. Wender PA; Baryza JL; Bennett CE; Bi FC; Brenner SE; Clarke MO; Horan JC; Kan C; Lacôte E; Lippa B; Nell PG; Turner TM J Am Chem Soc; 2002 Nov; 124(46):13648-9. PubMed ID: 12431074 [TBL] [Abstract][Full Text] [Related]
2. The bryostatins inhibit growth of B16/F10 melanoma cells in vitro through a protein kinase C-independent mechanism: dissociation of activities using 26-epi-bryostatin 1. Szallasi Z; Du L; Levine R; Lewin NE; Nguyen PN; Williams MD; Pettit GR; Blumberg PM Cancer Res; 1996 May; 56(9):2105-11. PubMed ID: 8616857 [TBL] [Abstract][Full Text] [Related]
4. The design, computer modeling, solution structure, and biological evaluation of synthetic analogs of bryostatin 1. Wender PA; DeBrabander J; Harran PG; Jimenez JM; Koehler MF; Lippa B; Park CM; Siedenbiedel C; Pettit GR Proc Natl Acad Sci U S A; 1998 Jun; 95(12):6624-9. PubMed ID: 9618462 [TBL] [Abstract][Full Text] [Related]
5. The role of protein kinase C isoenzymes in the growth inhibition caused by bryostatin 1 in human A549 lung and MCF-7 breast carcinoma cells. Stanwell C; Gescher A; Bradshaw TD; Pettit GR Int J Cancer; 1994 Feb; 56(4):585-92. PubMed ID: 8112895 [TBL] [Abstract][Full Text] [Related]
6. The rational design of potential chemotherapeutic agents: synthesis of bryostatin analogues. Wender PA; Hinkle KW; Koehler MF; Lippa B Med Res Rev; 1999 Sep; 19(5):388-407. PubMed ID: 10502742 [TBL] [Abstract][Full Text] [Related]
7. Effects of bryostatins 1 and 2 on morphological and functional differentiation of SH-SY5Y human neuroblastoma cells. Jalava AM; Heikkilä J; Akerlind G; Pettit GR; Akerman KE Cancer Res; 1990 Jun; 50(11):3422-8. PubMed ID: 2334938 [TBL] [Abstract][Full Text] [Related]
8. Chemistry and clinical biology of the bryostatins. Mutter R; Wills M Bioorg Med Chem; 2000 Aug; 8(8):1841-60. PubMed ID: 11003129 [TBL] [Abstract][Full Text] [Related]
9. Bryostatin-1: a novel PKC inhibitor in clinical development. Kortmansky J; Schwartz GK Cancer Invest; 2003; 21(6):924-36. PubMed ID: 14735696 [TBL] [Abstract][Full Text] [Related]
10. Bryostatin 1 affects P-glycoprotein phosphorylation but not function in multidrug-resistant human breast cancer cells. Scala S; Dickstein B; Regis J; Szallasi Z; Blumberg PM; Bates SE Clin Cancer Res; 1995 Dec; 1(12):1581-7. PubMed ID: 9815959 [TBL] [Abstract][Full Text] [Related]
11. Sensitization of human cervical carcinoma cells to cis-diamminedichloroplatinum(II) by bryostatin 1. Basu A; Lazo JS Cancer Res; 1992 Jun; 52(11):3119-24. PubMed ID: 1591725 [TBL] [Abstract][Full Text] [Related]
12. Synthesis of a simplified bryostatin C-ring analogue that binds to the CRD2 of human PKC-alpha and construction of a novel BC-analogue by an unusual Julia olefination process. Hale KJ; Frigerio M; Manaviazar S; Hummersone MG; Fillingham IJ; Barsukov IG; Damblon CF; Gescher A; Roberts GC Org Lett; 2003 Feb; 5(4):499-502. PubMed ID: 12583753 [TBL] [Abstract][Full Text] [Related]
13. Selective binding of bryostatin analogues to the cysteine rich domains of protein kinase C isozymes. Wender PA; Lippa B; Park CM; Irie K; Nakahara A; Ohigashi H Bioorg Med Chem Lett; 1999 Jun; 9(12):1687-90. PubMed ID: 10397502 [TBL] [Abstract][Full Text] [Related]
14. Bryostatin 1 protects protein kinase C-delta from down-regulation in mouse keratinocytes in parallel with its inhibition of phorbol ester-induced differentiation. Szallasi Z; Denning MF; Smith CB; Dlugosz AA; Yuspa SH; Pettit GR; Blumberg PM Mol Pharmacol; 1994 Nov; 46(5):840-50. PubMed ID: 7969070 [TBL] [Abstract][Full Text] [Related]
15. In vivo administration of the anticancer agent bryostatin 1 activates platelets and neutrophils and modulates protein kinase C activity. Berkow RL; Schlabach L; Dodson R; Benjamin WH; Pettit GR; Rustagi P; Kraft AS Cancer Res; 1993 Jun; 53(12):2810-5. PubMed ID: 8504423 [TBL] [Abstract][Full Text] [Related]
16. Establishment of a murine leukaemia cell line resistant to the growth-inhibitory effect of bryostatin 1. Prendiville J; McGown AT; Gescher A; Dickson AJ; Courage C; Pettit GR; Crowther D; Fox BW Br J Cancer; 1994 Oct; 70(4):573-8. PubMed ID: 7917900 [TBL] [Abstract][Full Text] [Related]
17. p53 and protein kinase C independent induction of growth arrest and apoptosis by bryostatin 1 in a highly metastatic mammary epithelial cell line: In vitro versus in vivo activity. Wang H; Mohammad RM; Werdell J; Shekhar PV Int J Mol Med; 1998 Jun; 1(6):915-23. PubMed ID: 9852625 [TBL] [Abstract][Full Text] [Related]
18. Simplified analogs of bryostatin with anticancer activity display greater potency for translocation of PKCdelta-GFP. Baryza JL; Brenner SE; Craske ML; Meyer T; Wender PA Chem Biol; 2004 Sep; 11(9):1261-7. PubMed ID: 15380186 [TBL] [Abstract][Full Text] [Related]
19. Disparity in expression of protein kinase C alpha in human glioma versus glioma-derived primary cell lines: therapeutic implications. Zellner A; Fetell MR; Bruce JN; De Vivo DC; O'Driscoll KR Clin Cancer Res; 1998 Jul; 4(7):1797-802. PubMed ID: 9676858 [TBL] [Abstract][Full Text] [Related]
20. Bryostatin 1 enhances lymphokine activated killer sensitivity and modulates the beta 1 integrin profile of cultured human tumor cells. Correale P; Caraglia M; Fabbrocini A; Guarrasi R; Pepe S; Patella V; Marone G; Pinto A; Bianco AR; Tagliaferri P Anticancer Drugs; 1995 Apr; 6(2):285-90. PubMed ID: 7540894 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]